Investor
Remedium Capital Partners, LLC
CIK 0002104501 · filed 2026-05-19 · SEC filing
13F book
$281.2M
Positions
6
Largest name
27.3%
Oruka Therapeutics, Inc. · ORKA
Est. mark
$230.5M
Price effect on 6 names still held. Flow $50.5M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Oruka Therapeutics, Inc. | ORKA | 1.57M | $76.8M | 27.3% | $76.1M | Added$76.7M |
| Spyre Therapeutics, Inc. | SYRE | 1.46M | $73.5M | 26.1% | $73.4M | Held |
| Galecto Inc | DMRA | 2.05M | $53M | 18.8% | $3.12M | Added$53M |
| Apogee Therapeutics, Inc. | APGE | 583.6K | $49.1M | 17.5% | $49.1M | Held |
| Jade Biosciences, Inc. | JBIO | 1.58M | $22.2M | 7.9% | $22.1M | Held |
| Crescent Biopharma, Inc. | CBIO | 361.3K | $6.64M | 2.4% | $6.63M | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.